Literature DB >> 23289593

Three-dimensionally engineered biomimetic tissue models for in vitro drug evaluation: delivery, efficacy and toxicity.

Yvonne Peck1, Dong-An Wang.   

Abstract

INTRODUCTION: Three-dimensionally (3D) engineered biomimetic tissue models are sought after due to their high fidelity in mimicking various native tissues of the human body, this quality of which gives them an important role at the forefront of drug discovery and development. A multitude of studies have consistently indicated that gene expression profiles, cellular phenotypes, differentiation capabilities and functionalities are all affected by tissue architecture. Thus, the drug evaluation process will stand to gain immense benefits from the fairly accurate predictions of cellular responses displayed by 3D-engineered tissue models when exposed to the drugs of interest in vitro. Stemming from this fact, many studies have set out to capitalize on developing tissue models that are tailored to specific aspects of drug evaluation including the tests of novel drug delivery systems, drug efficacy and toxicity. AREAS COVERED: The areas covered include fabrication methods and usage of 3D in vitro tumor models in cancer research, focusing on the evaluation of delivery and efficacy of various anticancer drugs or other therapeutic agents. Also covered are the use of 3D in vitro inflammatory tissue models in anti-inflammation research, centering on osteoarthritis (OA) and rheumatoid arthritis (RA) and the use of 3D in vitro tissue models designed for drug toxicity evaluation specifically with liver-mimetic tissues. EXPERT OPINION: Currently available 3D tissue models in various fields of research have already displayed their capabilities in predicting cellular responses to various therapeutic agents and delivery methods with better accuracy than their 2D counterparts, albeit being in need of much refinement before they can be successfully applied for reliable drug evaluation. Given further development and improvement, it is highly probable that the 3D-engineered tissue models may perform as living platforms for dynamic drug evaluation in vitro.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23289593     DOI: 10.1517/17425247.2013.751096

Source DB:  PubMed          Journal:  Expert Opin Drug Deliv        ISSN: 1742-5247            Impact factor:   6.648


  10 in total

Review 1.  Status of acute systemic toxicity testing requirements and data uses by U.S. regulatory agencies.

Authors:  Judy Strickland; Amy J Clippinger; Jeffrey Brown; David Allen; Abigail Jacobs; Joanna Matheson; Anna Lowit; Emily N Reinke; Mark S Johnson; Michael J Quinn; David Mattie; Suzanne C Fitzpatrick; Surender Ahir; Nicole Kleinstreuer; Warren Casey
Journal:  Regul Toxicol Pharmacol       Date:  2018-02-03       Impact factor: 3.271

2.  Novel Nystatin A₁ derivatives exhibiting low host cell toxicity and antifungal activity in an in vitro model of oral candidosis.

Authors:  Joanna Boros-Majewska; Natalia Salewska; Edward Borowski; Sławomir Milewski; Sladjana Malic; Xiao-Qing Wei; Anthony J Hayes; Melanie J Wilson; David W Williams
Journal:  Med Microbiol Immunol       Date:  2014-06-13       Impact factor: 3.402

3.  Comparative studies of cellular viability levels on 2D and 3D in vitro culture matrices.

Authors:  M Gargotti; U Lopez-Gonzalez; H J Byrne; A Casey
Journal:  Cytotechnology       Date:  2017-09-18       Impact factor: 2.058

Review 4.  Anti-Cancer Drug Validation: the Contribution of Tissue Engineered Models.

Authors:  Mariana R Carvalho; Daniela Lima; Rui L Reis; Joaquim M Oliveira; Vitor M Correlo
Journal:  Stem Cell Rev Rep       Date:  2017-06       Impact factor: 5.739

5.  Coupling Micro-Physiological Systems and Biosensors for Improving Cancer Biomarkers Detection.

Authors:  Virginia Brancato; Rui L Reis; Subhas C Kundu
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

6.  Dual-stage growth factor release within 3D protein-engineered hydrogel niches promotes adipogenesis.

Authors:  Midori Greenwood-Goodwin; Eric S Teasley; Sarah C Heilshorn
Journal:  Biomater Sci       Date:  2014-11-01       Impact factor: 6.843

Review 7.  Applying refinement to the use of mice and rats in rheumatoid arthritis research.

Authors:  Penny Hawkins; Rachel Armstrong; Tania Boden; Paul Garside; Katherine Knight; Elliot Lilley; Michael Seed; Michael Wilkinson; Richard O Williams
Journal:  Inflammopharmacology       Date:  2015-07-14       Impact factor: 4.473

Review 8.  Biomaterial-based delivery systems of nucleic acid for regenerative research and regenerative therapy.

Authors:  Jun-Ichiro Jo; Jian-Qing Gao; Yasuhiko Tabata
Journal:  Regen Ther       Date:  2019-07-11       Impact factor: 3.419

9.  Engineering anisotropic biomimetic fibrocartilage microenvironment by bioprinting mesenchymal stem cells in nanoliter gel droplets.

Authors:  Umut A Gurkan; Rami El Assal; Simin E Yildiz; Yuree Sung; Alexander J Trachtenberg; Winston P Kuo; Utkan Demirci
Journal:  Mol Pharm       Date:  2014-03-13       Impact factor: 4.939

10.  Evaluation of surrogate tissues as indicators of drug activity in a melanoma skin model.

Authors:  Palak R Parekh; Rohini Choudhuri; Urbain Weyemi; Olga A Martin; William M Bonner; Christophe E Redon
Journal:  Cancer Med       Date:  2016-06-23       Impact factor: 4.452

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.